Effectiveness of Postoperative Irradiation in Stage IIIA Non–Small Cell Lung Cancer According to Regression Tree Analyses of Recurrence Risks

Sawyer, Timothy; Bonner, James A.; Gould, Perry M.; Foote, Robert L.; Deschamps, Claude; Trastek, Victor F.; Pairolero, Peter C.; Allen, Mark S.; Lange, Carla M.; Li, Hongzhe

doi:10.1016/s0003-4975(97)00908-9

Cited by 66 publications

(33 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[21][22][23][24][35][36] Of the 10 randomized trials, 5-15 a similar trend was found in only 2 main analyses. 11,13 The rate of local recurrences at 5 years in resected nonsmall cell lung carcinoma is reported to be 6 -10% for Stage I disease, 25-35% for Stage II disease, and up to 75% for Stage III disease.…”

Section: Discussionmentioning

confidence: 62%

A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma

Dautzenberg

Arriagada

Chammard

et al. 1999

Cancer

234

110

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 62%

A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma

Dautzenberg

Arriagada

Chammard

et al. 1999

Cancer

234

110

View full text Add to dashboard Cite

“…The risk for local recurrence is lower with PORT (25%-35%), as shown in several retrospective studies listed in Table 1 [13][14][15][16][17][18][19]. In most of these studies, there was a historical comparison with patients who had no PORT, so these figures should be interpreted with caution.…”

Section: Studies Evaluating Portmentioning

confidence: 99%

Role of Postoperative Radiotherapy in Resected Non-Small Cell Lung Cancer: A Reassessment Based on New Data

Péchoux

2011

The Oncologist

117

View full text Add to dashboard Cite

After completing this course, the reader will be able to: 1. Identify patients with non-small cell lung cancer who may benefit from postoperative radiotherapy based upon current evidence. 2. Summarize the results of analyses of both older and more recent data regarding postoperative radiotherapy in NSCLC patients. ABSTRACT In completely resected non-small cell lung cancer (NSCLC) patients with pathologically involved mediasti-nal lymph nodes (N2), administration of adjuvant platinum based chemotherapy is now considered the standard of care, based on level 1 evidence. The role of postoperative radiation therapy (PORT) in this group of patients remains controversial. The PORT meta-analysis published in 1998 concluded that adjuvant radiotherapy was detrimental to patients with early-stage completely resected NSCLC, but that the role of PORT in the treatment of tumors with N2 involvement was unclear, and that further research was warranted. Recent retrospective and non-randomized studies, as well as subgroup analyses of recent randomized trials evaluating adjuvant chemotherapy, provide evidence of the possible benefit of PORT in patients with mediastinal nodal involvement. The role of PORT is also a valid question in patients with proven N2 disease who have undergone only induction chemotherapy followed by surgery, because the local recurrence rate for such patients varies in the range of 20%-60%. Based on the currently available data, PORT should be discussed for fit patients with completely resected NSCLC with N2 nodal involvement, preferably after completion of adju-vant chemotherapy. There is a need for new randomized evidence to evaluate PORT using the modern three-dimensional conformal radiation technique, with attention paid to reducing the risk for, particularly, pulmonary and cardiac toxicity. A new large multi-institutional randomized trial evaluating PORT in this patient population is needed and now under way. The Oncologist 2011;16:672-681

show abstract

“…Следующее исследование было ограничено IIIA ста-дией НМРЛ у 224 пациентов, в том числе 88 больных, по-лучивших ПОРТ СОД 50,4 Гр [27]. Пациенты с высоким и средним риском (в зависимости от количества и распо-ложения пораженных лимфатических узлов pN1 и pN2) получили наилучшие показатели местного контроля и об-щей выживаемости, хотя преимущество в общей выжи-ваемости были у пациентов высокого риска (p = 0.0002).…”

Section: рак легкогоunclassified

Postoperative Radiotherapy of Non-Small Cell Lung Cancer

Муфазалов¹,

Шарипова²

2015

Zlokač. opuholi

View full text Add to dashboard Cite

Effectiveness of Postoperative Irradiation in Stage IIIA Non–Small Cell Lung Cancer According to Regression Tree Analyses of Recurrence Risks

Cited by 66 publications

References 26 publications

A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma

A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma

Role of Postoperative Radiotherapy in Resected Non-Small Cell Lung Cancer: A Reassessment Based on New Data

Postoperative Radiotherapy of Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About